Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04988152 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the PK, Safety, and Tolerability of Sotrovimab vs Placebo Administered IV or IM in Japanese and Caucasian Participants
A Phase 1 study, sponsored by Vir Biotechnology.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT04988152 is a Phase 1 study that has completed, run by Vir Biotechnology. The registered enrollment target is 48 participants.
The verdict
NCT04988152, a Phase 1 study, has completed, sponsored by Vir Biotechnology.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
This is a Phase I single-dose study to investigate the pharmacokinetics, safety, and tolerability of sotrovimab vs placebo by intravenous or intramuscular administration in healthy Japanese and Caucasian participants.
Interventions
- BIOLOGICAL sotrovimab
- OTHER Placebo to Biologic
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2021-07-06 |
| Est. Completion | 2021-12-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04988152
The ClinicalTrials.gov registry entry for NCT04988152 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vir Biotechnology, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which sotrovimab is the first listed.
NCT04988152 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04988152 about?
NCT04988152 is a clinical study titled "A Study to Investigate the PK, Safety, and Tolerability of Sotrovimab vs Placebo Administered IV or IM in Japanese and Caucasian Participants". This is a Phase I single-dose study to investigate the pharmacokinetics, safety, and tolerability of sotrovimab vs placebo by intravenous or intramuscular administration in healthy Japanese and Caucasian participants.
What is the current status of trial NCT04988152?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2021-07-06. Estimated completion is 2021-12-07.
What interventions are being tested in trial NCT04988152?
The interventions under investigation include: sotrovimab (BIOLOGICAL), Placebo to Biologic (OTHER).
Who is sponsoring clinical trial NCT04988152?
This trial is sponsored by Vir Biotechnology, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.